Skip to content

Clinical features and survival analysis of Langerhans histiocytosis in children

Clinical features and survival analysis of Langerhans histiocytosis in children

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099334
Enrollment
Unknown
Registered
2025-03-21
Start date
2024-11-10
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Langerhans histiocytosis in children

Interventions

Observation group:None

Sponsors

Wuhan Childrens Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Diagnostic criteria for confirmed LCH: All patients must have histopathological examination results from lesion biopsy, with immunohistochemical staining positive for CD1a and/or CD207 (i.e., Langerin), or the presence of Birbeck granules can be identified under electron microscopy. 2.Age < 18 years. 3.Standardized treatment and follow-up.

Exclusion criteria

Exclusion criteria: 1.The diagnosis of LCH was not confirmed by biopsy, such as having typical pathological findings and positive CD1a and/or Langerin staining. 2.Patients who did not receive treatment at our hospital after the initial diagnosis of LCH, or who did not follow medical advice for standardized treatment. 3.Patients who were lost to follow-up.

Design outcomes

Primary

MeasureTime frame
Recurrence;

Countries

China

Contacts

Public ContactXuehong Liang

Wuhan Childrens Hospital

liangxuehong@zgwhfe.com+86 15717119087

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026